Genetic testing for embryos during in vitro fertilization involves two distinct billing components: clinic procedural fees for the embryology biopsy and cryopreservation, and separate reference genetics laboratory fees for the diagnostic analysis. Total out-of-pocket costs vary based on whether testing covers chromosomal screening (PGT-A), single-gene disorders (PGT-M), or structural rearrangements (PGT-SR), the number of embryos biopsied, batch pricing arrangements, and whether health insurance covers diagnostic indications.
Preimplantation genetic testing allows fertility specialists to evaluate the chromosomal or genetic status of embryos before a transfer takes place. Because embryo testing is an add-on procedure to standard in vitro fertilization (IVF), understanding how clinics and outside reference laboratories structure their fees is essential for accurate financial planning.
How Embryo Genetic Testing Fits Into In Vitro Fertilization
Preimplantation genetic testing is performed exclusively in conjunction with an in vitro fertilization cycle. After eggs are retrieved and fertilized in the embryology laboratory, resulting embryos are cultured until they reach the blastocyst stage, typically on day five, six, or seven of development. At this point, an embryologist carefully removes a small sample of cells from the trophectoderm, the outer cell layer destined to form the placenta, leaving the inner cell mass that develops into the fetus intact.
Once the biopsy is complete, the embryos are immediately frozen through vitrification and stored in the clinic liquid nitrogen tanks while the biopsied cellular material is prepared and shipped to a specialized reference genetics laboratory. Because assisted reproductive technology outcomes depend on numerous patient, laboratory, and clinical variables, testing is used selectively to identify embryos with the expected number of chromosomes or to screen out specific inherited genetic conditions prior to transfer.
Undergoing embryo testing requires careful coordination between your primary fertility clinic and an independent genetics diagnostic company. Each facility operates under its own clinical protocols, billing structures, and financial policies, which means patients generally receive separate communications, consent forms, and itemized invoices from both entities throughout a single treatment cycle.
Further reading: CDC: Assisted Reproductive Technology
Further reading: ACOG: Evaluating Infertility
The Dual-Bill Structure: Clinic Biopsy Fees Versus Reference Lab Testing
The most common financial surprise for IVF patients is discovering that embryo genetic testing is split across two completely independent organizations. Your reproductive endocrinology clinic performs the physical procedure, while a third-party molecular genetics laboratory carries out the high-throughput sequencing or diagnostic analysis of the biopsied cells.
Your fertility clinic bill covers embryology laboratory services. These clinical components include the micromanipulation required to laser-assist the hatching of the embryo shell, the manual cellular biopsy performed under high-magnification microscopy, post-biopsy vitrification to safely freeze the embryos, specialized shipping preparation, and ongoing liquid nitrogen cryostorage. Even if an outside lab offers promotional pricing on the diagnostic side, your fertility center charges for the technical skill and time required to extract the cellular samples safely.
Conversely, the reference genetics laboratory bills separately for the actual genetic sequencing, interpretation, and diagnostic reporting. Their invoice covers cellular DNA amplification, next-generation sequencing assays, bioinformatics analysis, and genetic counseling consultations to review the clinical report. Because these two organizations bill independently, paying your clinic fee does not settle your balance with the testing laboratory, and vice versa.
PGT-A, PGT-M, and PGT-SR: How Testing Complexity Changes Billing
Embryo testing is divided into three distinct diagnostic categories, and the specific test ordered by your reproductive endocrinologist directly determines the complexity and total cost of the laboratory work. The most common form is Preimplantation Genetic Testing for Aneuploidies (PGT-A), which screens for missing or extra whole chromosomes (such as trisomies or monosomies). Because PGT-A uses standardized, high-throughput sequencing platforms across pooled patient samples, reference labs typically offer standardized tier pricing for this test.
Preimplantation Genetic Testing for Monogenic or Single-Gene Disorders (PGT-M) is ordered when one or both intended parents carry a known hereditary mutation for a specific genetic disease, such as cystic fibrosis, sickle cell anemia, or Huntington's disease. PGT-M requires custom test development before the IVF cycle begins. Molecular geneticists must collect DNA samples from both biological parents, and often extended family members, to build an individualized molecular probe or linkage map. This upfront probe design phase carries a dedicated non-refundable development fee before any embryo biopsy analysis can take place.
Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR) is utilized when a parent carries a balanced chromosomal translocation or inversion. PGT-SR detects whether an embryo inherited a normal, balanced, or unbalanced chromosomal arrangement. Like PGT-M, structural testing frequently requires pre-cycle protocol validation by laboratory geneticists to confirm the assay can accurately differentiate between normal and unbalanced genetic material in tiny cellular samples, resulting in higher laboratory fees than routine aneuploidy screening alone.
Further reading: ACOG: Evaluating Infertility
Per-Embryo Fees, Batch Pricing, and Multi-Cycle Banking Factors
Reference genetics laboratories generally structure their pricing models around either a flat-rate batch package or an itemized per-embryo fee schedule. In a batch pricing model, the laboratory charges a base rate that covers testing for an established number of embryos—commonly up to four, six, or eight embryos per retrieval cycle. If your retrieval yields more blastocysts than the base package accommodates, an incremental per-embryo surcharge applies to every additional sample tested beyond that cap.
Alternatively, some laboratories operate on a strict per-embryo billing schedule, where you are charged solely for the exact number of embryos biopsied without any baseline package inclusion. For individuals with low blastocyst yields, a per-embryo model can be more cost-effective. However, for patients who generate a higher-than-average number of embryos, flat-rate batch structures usually offer a lower average cost per screened embryo.
For patients undergoing embryo banking across multiple egg retrieval cycles, batch rules become critical. Some reference laboratories allow patients to combine biopsies from two separate retrieval cycles into a single testing batch under one fee, provided all biopsies arrive within a defined calendar window (such as six months). Other facilities require a completely fresh baseline batch fee for each individual egg retrieval, regardless of how few blastocysts were biopsied in a given cycle. Clarifying these batch accumulation policies upfront is essential if multi-cycle banking is part of your clinical treatment plan.
Further reading: CDC: Assisted Reproductive Technology
Overlooked Associated Expenses: Cryostorage, Shipping, and Re-Biopsy Costs
Calculating the full expense of embryo testing requires looking beyond the basic biopsy and sequencing fees. Because embryos must remain cryopreserved while genetic testing results are pending—a process that typically takes one to three weeks—patients must factor in the ongoing costs of tissue storage. Most clinics include a short initial storage period (such as one to three months) within the standard IVF cycle agreement, but ongoing cryostorage billed on a monthly, quarterly, or annual basis applies thereafter until embryo transfer occurs.
Medical courier transportation is another standard out-of-pocket expense. Because biopsied cellular DNA must be transported under temperature-controlled, expedited conditions to the diagnostic laboratory, clinics contract with specialized medical couriers and pass shipping logistics charges directly to the patient. If you utilize different specialized laboratories for simultaneous PGT-M and PGT-A analysis, dual shipping fees may apply.
Patients must also prepare for inconclusive or mosaic outcomes that may lead to re-biopsy considerations. Occasionally, an embryo biopsy yields insufficient DNA or an indeterminate result. If a clinical decision is made to thaw, re-biopsy, re-vitrify, and re-test that embryo in a subsequent cycle, both the clinic and the diagnostic laboratory may assess technical handling and testing fees for the repeat analysis.
Insurance Navigation, Medical Necessity, and Billing Codes for Embryo Testing
Health insurance coverage for embryo genetic testing varies significantly based on employer plan design, state-mandated fertility coverage laws, and clinical medical necessity criteria. Standard PGT-A is widely classified by commercial insurance payers as an elective screening tool, meaning it is rarely covered under standard health plans even when general IVF benefits exist.
In contrast, PGT-M and PGT-SR may meet medical necessity guidelines under specific health plans if the intended parents are verified carriers of severe autosomal recessive or dominant genetic mutations, or if there is a documented history of recurrent pregnancy loss linked to parental chromosomal rearrangements. In these situations, your clinical team must submit comprehensive medical documentation, carrier screening reports, and specific procedural coding (such as CPT codes for biopsy micromanipulation, DNA extraction, and molecular cytogenetic analysis) to obtain prior authorization.
Even when an insurer issues a prior authorization for genetic testing, patients must verify whether both the treating clinic and the outside reference laboratory participate as in-network providers. A pre-authorization granted for an in-network fertility center does not automatically apply to an out-of-network genetics laboratory, which could leave you responsible for out-of-network balance billing on the diagnostic sequencing portion.
Further reading: ACOG: Evaluating Infertility
How to Audit an IVF Clinic Financial Agreement Before Starting a Biopsy Cycle
Before consenting to an egg retrieval cycle that incorporates preimplantation genetic testing, request an itemized, line-by-line financial disclosure document from both your reproductive endocrinology practice and the selected genetics laboratory. Never rely on bundled verbal estimates, which frequently omit third-party lab processing or cryopreservation maintenance fees.
Review the clinic agreement specifically for biopsy tier thresholds and refund policies. If your retrieval cycle results in zero blastocysts suitable for biopsy, confirm whether your pre-paid embryology biopsy fee is fully refunded or credited toward a future treatment attempt. Similarly, verify whether your clinic charges a flat biopsy fee regardless of embryo count or tiers the cost based on whether one embryo or ten embryos are biopsied.
Directly contact the financial coordination team at the outside genetics testing laboratory to request their self-pay fee schedule, contracted insurance rates, and prompt-pay discounts. Ask whether genetic counseling services before and after testing are included in the base diagnostic rate, and verify the deadline by which testing invoices must be settled to avoid administrative holds on your diagnostic reports.
Frequently asked questions
What is the difference between clinic biopsy fees and reference lab fees?
Clinic biopsy fees cover the physical embryology procedure where cells are removed from the blastocyst, prepared, and frozen at your fertility center. Reference lab fees are billed separately by an independent genetics laboratory to perform DNA sequencing, diagnostic interpretation, and clinical reporting.
Does insurance cover preimplantation genetic testing for embryos?
Coverage depends on your specific insurance policy and medical indication. Routine PGT-A is rarely covered because insurers typically view it as elective, but targeted testing such as PGT-M or PGT-SR may qualify for coverage with prior authorization if there is a documented medical history of known genetic disease or structural chromosomal rearrangements.
What happens financially if no embryos reach the blastocyst stage for biopsy?
If an IVF cycle does not produce blastocysts of sufficient quality to undergo biopsy, the outside reference lab will not charge for diagnostic testing. Most fertility clinics will refund or credit the pre-paid embryology biopsy fee, though standard monitoring, retrieval, and fertilization charges remain non-refundable.
Can I combine embryos from multiple retrieval cycles into one genetic test batch?
Some reference genetics laboratories allow multi-cycle banking, enabling patients to group biopsied embryos from separate retrievals into one testing batch within a designated timeframe. However, individual laboratory policies vary, and some facilities charge a full baseline batch fee for each individual retrieval cycle.
Your next step
Request itemized written financial quotes from both your fertility clinic and the partnered genetics reference laboratory to verify biopsy tiers, shipping fees, batch caps, and refund policies before your retrieval cycle begins.